Psilocybin Through History: A Timeline

Psilocybin Through History: A Timeline

Psilocybin mushrooms have been part of human culture for thousands of years. The modern scientific story is only 70 years old. The indigenous story is immeasurably older. What follows is a chronological account of psilocybin's documented history — from prehistoric evidence through the 2026 therapeutic landscape.

Prehistoric and Pre-Columbian Era

~9,000–7,000 BCE — Tassili n'Ajjer Cave Art (Algeria)

The Tassili n'Ajjer cave complex in southern Algeria contains rock paintings depicting mushroom-holding anthropomorphic figures. Some researchers, including ethnomycologist Giorgio Samorini, interpret these as evidence of ritual mushroom use among prehistoric North African peoples. The dating is contested, but the imagery is striking: figures with mushrooms growing from their bodies, connected to geometric patterns consistent with visionary experience.

~3,500 BCE — Selva Pascuala Murals (Spain)

A cave painting at Selva Pascuala in Villar del Humo, Cuenca, Spain depicts what appears to be Psilocybe hispanica mushrooms alongside a bull figure. The mushrooms are depicted in rows, suggesting ritual or agricultural context. This is currently considered the oldest direct archaeological evidence of Psilocybe in Europe.

Pre-Columbian Mesoamerica — The Velada Tradition

Archaeological evidence from multiple Mesoamerican cultures — Mazatec, Zapotec, Mixtec — documents ritual mushroom use extending at least 3,000 years. Mushroom stones (stone carvings in the form of mushrooms with human faces at the base) have been found at sites across Guatemala and southern Mexico. The Mazatec velada ceremony — an all-night healing ritual conducted by a curandera or curandero using psilocybin mushrooms — remains practiced in Oaxaca today, its lineage unbroken.

16th–19th Century: Colonial Suppression

1502 — First Spanish Accounts of "Teonanácatl"

Spanish chroniclers record "teonanácatl" (the Nahuatl term, roughly translated as "flesh of the gods") used in Aztec coronation ceremonies. Franciscan friar Bernardino de Sahagún documents mushroom use in his monumental Florentine Codex (1569), noting that after consumption "they saw visions and had revelations of the future."

1620 — Inquisition Suppression

The Spanish Inquisition officially condemns indigenous sacred mushroom use as demonic practice, driving ceremonies underground. Ritual mushroom use survives in remote mountain villages of Oaxaca and Veracruz, preserved by Mazatec, Zapotec, and Mixtec communities through four centuries of colonial and post-colonial pressure.

1799 — First European Scientific Botanical Record

British naturalist James Sowerby documents a case of accidental Psilocybe semilanceata (Liberty Cap) ingestion by a London family who picked the mushrooms in Green Park. The family experienced visual disturbances, loss of time perception, and "fits of immoderate laughter." This is the first recorded case of accidental psilocybin mushroom ingestion in European scientific literature.

20th Century: Discovery and Prohibition

1936–1938 — Schultes Documents the Mazatec Velada

Harvard ethnobotanist Richard Evans Schultes travels to Oaxaca and documents Mazatec ceremonial mushroom use, conducting the first academic description of the contemporary velada ceremony. He identifies the mushrooms as Panaeolus sphinctrinus — an identification later revised to Psilocybe species.

1955 — R. Gordon Wasson's Mazatec Expedition

New York banker and amateur mycologist R. Gordon Wasson and his wife Valentina Pavel Wasson travel to Huautla de Jiménez, Oaxaca, and participate in a velada ceremony with curandera María Sabina. Wasson is believed to be among the first Westerners to participate in a traditional mushroom ceremony. His 1957 Life magazine article — "Seeking the Magic Mushroom" — introduces psilocybin mushrooms to mass Western consciousness.

1958 — Albert Hofmann Isolates Psilocybin and Psilocin

Swiss chemist Albert Hofmann — who had already discovered LSD in 1943 — isolates the active compounds from Psilocybe mexicana specimens provided by Wasson. Working at Sandoz Laboratories in Basel, Hofmann identifies psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin (4-hydroxy-N,N-dimethyltryptamine) and publishes the first synthesis of both compounds. Hofmann self-experiments with extracted psilocybin, confirming its psychoactive properties.

1960 — Harvard Psilocybin Project Begins

Timothy Leary and Richard Alpert (later Ram Dass) begin administering psilocybin to graduate students, prisoners (the Concord Prison Experiment), and religious personnel (the Marsh Chapel Experiment, also called the "Good Friday Experiment") at Harvard University. The Concord Prison Experiment shows initial promising recidivism reduction — results later contested. The Marsh Chapel Experiment shows significant mystical experiences in 90% of participants — findings replicated 25 years later.

1962 — Marsh Chapel Experiment (Good Friday Experiment)

Walter Pahnke, under Leary's supervision, conducts the Marsh Chapel Experiment: 20 seminarians receive either psilocybin or niacin (placebo) on Good Friday in Marsh Chapel, Boston University. Nine of ten psilocybin recipients report mystical experiences. This becomes one of the most discussed studies in the psychology of religion. A 25-year follow-up by Rick Doblin (1991) confirms sustained positive effects in all surviving psilocybin recipients.

1963 — Harvard Firing

Leary and Alpert are dismissed from Harvard for giving psilocybin to undergraduates in violation of the terms of their research. The incident marks the beginning of the politicization of psychedelic research and accelerates the cultural association of psilocybin with counterculture radicalism.

1970 — Controlled Substances Act: Schedule I

The US Controlled Substances Act classifies psilocybin as Schedule I — "no accepted medical use, high potential for abuse." Research halts almost completely in the US and most Western countries. The legal framework that would delay therapeutic research by 30 years is established.

1975–1976 — Psilocybin Mushroom Cultivation Goes Underground

The publication of Psilocybin: Magic Mushroom Grower's Guide by O.T. Oss and O.N. Oeric (pseudonyms for Terence and Dennis McKenna) introduces the first practical cultivation instructions for Psilocybe cubensis. Home cultivation of psilocybin mushrooms begins to spread as a subculture distinct from the pharmaceutical supply that existed before prohibition.

1991 — Mycelium Running and Paul Stamets' Influence Begins

Mycologist Paul Stamets publishes early work on mushroom cultivation and ecology. His later book Mycelium Running (2005) and Psilocybin Mushrooms of the World (1996) become definitive references for both mycological science and the cultivation community.

The Psychedelic Renaissance: 1990s–Present

1994 — Johns Hopkins University Begins Psilocybin Research

Roland Griffiths and colleagues at Johns Hopkins begin the modern clinical research program that will eventually become the Center for Psychedelic and Consciousness Research. Initial work is cautious and methodologically rigorous, deliberately distancing itself from the Leary-era association.

2006 — Landmark Johns Hopkins Mystical Experience Study

Griffiths et al. publish the landmark study in Psychopharmacology: psilocybin reliably occasions mystical experiences in healthy volunteers. 67% of participants rate the session among the "five most meaningful experiences of their lives." The paper triggers a wave of scientific interest and media coverage and is widely credited with launching the modern psychedelic renaissance.

2012 — First Modern Psilocybin for Cancer Anxiety Study (Pilot)

NYU pilot data shows psilocybin reduces anxiety and depression in cancer patients. Sets the stage for the 2016 landmark trials.

2016 — The Year of the Landmark Trials

Two simultaneously published studies (Journal of Psychopharmacology, December 2016):

• Griffiths et al. (Johns Hopkins): 80% of cancer patients show sustained reduction in depression and anxiety at 6 months
• Ross et al. (NYU): 83% response rate for anxiety in cancer patients at 7 weeks

These results — described by researchers as among the most significant in psychiatric history — trigger major media coverage and accelerate regulatory interest.

2018 — FDA Breakthrough Therapy Designations

FDA grants Breakthrough Therapy designation to COMPASS Pathways for psilocybin in treatment-resistant depression (TRD) and to Usona Institute for psilocybin in major depressive disorder (MDD). This expedites review pathways and signals FDA openness to therapeutic psilocybin.

2019 — Denver Decriminalizes; Oregon Moves Toward Legalization

Denver, Colorado becomes the first US city to decriminalize psilocybin mushrooms through a voter referendum. Oregon begins the process that leads to Measure 109.

2020 — Oregon Measure 109 Passes

Oregon voters pass Measure 109, creating the first licensed psilocybin service center framework in the United States. Oregon also passes Measure 110, decriminalizing personal use of all drugs. The two measures together represent the most significant psychedelic policy shift in the US since the 1970 CSA.

2022 — Colorado Proposition 122 Passes

Colorado voters pass Proposition 122 (the Natural Medicine Health Act), legalizing psilocybin, psilocin, DMT, mescaline (non-peyote), and ibogaine for supervised healing center use. Colorado's framework is broader than Oregon's, covering multiple substances and allowing limited personal use.

2023 — Oregon Service Centers Open; Australia Acts

Oregon's first licensed psilocybin service centers open for clients. Australia's TGA (Therapeutic Goods Administration) authorizes psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression, making Australia the first country to authorize psilocybin prescription at a federal level.

2023–2024 — COMPASS Phase 3 Trials Begin

COMPASS Pathways launches the largest psilocybin clinical trial in history — Phase 3 multi-center RCT for treatment-resistant depression at 100+ sites globally. Results expected 2025–2026 and will determine NDA submission to FDA.

2024 — Colorado Healing Centers Open; International Expansion

Colorado's natural medicine healing centers begin operating. Netherlands, Jamaica, and Costa Rica continue to see significant retreat center growth. Mexico's traditional ceremonial context expands to international wellness tourism.

2026 — Veterans Access Expansion (April Executive Order)

A US Executive Order in April 2026 establishes expedited VA-adjacent access pathways for veterans with treatment-resistant PTSD, formalizing a process for veterans to access psilocybin therapy under medical supervision without waiting for full FDA approval.

Key Figures in Psilocybin History

Albert Hofmann (1906–2008) — Swiss chemist who discovered LSD and first isolated psilocybin and psilocin. Author of LSD: My Problem Child.

R. Gordon Wasson (1898–1986) — Banker and ethnomycologist whose Life magazine article introduced psilocybin to the West.

María Sabina (1894–1985) — Mazatec curandera who hosted Wasson's 1955 ceremony, inadvertently catalyzing Western psychedelic interest. Spent her later years ambivalent about the outsider attention her cooperation had generated.

Timothy Leary (1920–1996) — Harvard psychologist whose advocacy made psilocybin culturally visible and politically radioactive simultaneously.

Roland Griffiths (1944–2023) — Johns Hopkins researcher who launched the modern research program. His 2006 paper is considered the foundational document of the psychedelic renaissance. He died of colon cancer in 2023, having himself experienced psilocybin therapy during his illness.

Paul Stamets (1955–) — Mycologist, author, and advocate. His intellectual contributions to both mycological science and psilocybin understanding span five decades.

Robin Carhart-Harris (1980–) — Neuroscientist at UCSF (formerly Imperial College London) whose neuroimaging work defined the default mode network theory of psilocybin action.

Rick Doblin (1953–) — Founder of MAPS (Multidisciplinary Association for Psychedelic Studies), the nonprofit that has been the primary force behind the modern clinical trial infrastructure for psychedelic therapy.